Acerus Pharma

143 articles with Acerus Pharma

• Acerus Reports First Quarter 2022 Financial Results

  5/10/2022

  Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2022.

• Acerus To Report Q1-2022 Financial Results And Host Investor Call

  5/5/2022

  Acerus Pharmaceuticals Corporation will announce its first quarter 2022 financial and operating results on Tuesday, May 10, 2022 before the market opens.

• Acerus Announces Completion of Share Consolidation - Apr 26, 2022

  4/26/2022

  Acerus Pharmaceuticals Corporation announced that further to its news release from April 19, 2022, the Company’s application to consolidate its common shares on the basis of one post-consolidation Share for every two hundred pre-consolidation Shares has been accepted by the Toronto Stock Exchange.

• Acerus Announces Share Consolidation - Apr 19, 2022

  4/19/2022

  Acerus Pharmaceuticals Corporation announced that the Company intends to undertake a consolidation of its outstanding common shares on the basis of one post-consolidation share for every two hundred pre-consolidation shares.

• Acerus Announces Amendments to Loan Facility

  3/31/2022

  Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc.

• Acerus Reports Fourth Quarter and Full Year 2021 Financial Results

  3/15/2022

  Acerus Pharmaceuticals Corporation reported its financial results for the three and twelve-month period ended December 31, 2021.

• Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call

  3/10/2022

  Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2021 financial and operating results on Tuesday, March 15, 2022 before the market opens.

• Acerus Announces Amendment to Loan Facilities

  2/18/2022

  Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Generation ”), a company affiliated with the Chairman of the Board of Directors of Acerus 1 , to increase its secured loan facility (the “ Loan Facility ”) from US$25 million to US$30.845 million.

• Acerus Announces Amendments to Loan Facilities

  12/13/2021

  Acerus Pharmaceuticals Corporation today announced that it has entered into an amending agreement with First Generation Capital Inc. to increase the existing subordinated secured loan facility from US$15 million to US$25 million.

• Acerus to Report Q3-2021 Financial Results and Host Investor Call

  11/2/2021

  Acerus Pharmaceuticals Corporation will announce its third quarter 2021 financial and operating results on Tuesday, November 9, 2021 before the market opens.

• Acerus Announces Participation in HC Wainwright Conference

  8/23/2021

  Acerus Pharmaceuticals Corporation today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15 in New York.

• Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation

  8/12/2021

  Acerus Pharmaceuticals Corporation today announced that it had accepted a Part 36 settlement offer made by Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB.

• Acerus Reports Fiscal 2021 Second Quarter Financial ResultsRevenue Triples after Buyback of US Rights for NATESTO®

  8/10/2021

  Acerus Pharmaceuticals Corporation today reported its financial results for the three and six-month period ended June 30, 2021.

• Acerus to Report Q2-2021 Financial Results and Host Investor Call

  8/3/2021

  Acerus Pharmaceuticals Corporation will announce its second quarter 2021 financial and operating results on Tuesday, August 10, 2021 before the market opens.

• Acerus Announces Voting Results for the 2021 Annual Meeting

  6/14/2021

  Acerus Pharmaceuticals Corporation announced the voting results from its annual meeting of shareholders held on June 14, 2021 in Toronto, Ontario.

• Acerus Reports First Quarter 2021 Financial Results

  5/13/2021

  Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2021.

• Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®

  5/10/2021

  Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that it has entered into a three-year agreement with Amneal Pharmaceuticals Inc. (“Amneal”) to co-promote NATESTO in the U.S. Endocrinology segment, leveraging the company’s extensive relationships with Endocrinology healthcare providers. Amneal will promote NATEST

• Acerus to Report Q1-2021 Financial Results and Host Investor Call

  5/6/2021

  Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its first quarter 2021 financial and operating results on Thursday, May 13, 2021 before the market opens. The company will also host a conference call on Thursday, May 13, 2021 at 10:00 a.m. Eastern Time.

• Acerus Announces Closing of US$15 Million Secured Loan Facility

  4/30/2021

  Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a US$15 million subordinated secured loan facility (the “ Loan Facility ”), which will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation Capital Inc.

• Acerus Announces Expansion of NATESTO® Distribution WorldwideMaylen Farma to Market Treatment in 20 Countries across Europe, Central Asia and the Middle East

  3/30/2021

  Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”), a speciality pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced the signing of an agreement granting Maylen Farma (“Maylen”) the exclusive rights to market NATESTO ® in 20 countries across Europe, Central Asia, and the Middle East.